Navigation Links
NicOx Signs Agreement With Capsugel for the Commercial Manufacture of Naproxcinod Oral Capsules
Date:9/23/2008

SOPHIA ANTIPOLIS, France, September 23 /PRNewswire-FirstCall/ -- NicOx S.A. (Euronext Paris: COX) today announced it has signed an exclusive agreement with Capsugel, the leading producer of two-piece capsules, for the commercial manufacturing and global supply of naproxcinod capsules. Naproxcinod is NicOx' lead investigational product and the first compound in the Cyclooxygenase-Inhibiting Nitric Oxide-Donating (CINOD) class of anti-inflammatory agents. The aim of this agreement is to ensure sufficient supplies of naproxcinod capsules to underpin its successful commercial launch. The filing of a New Drug Application (NDA) for naproxcinod with the U.S. Food and Drug Administration (FDA) is projected for mid-2009.

The agreement with Capsugel follows the signature of an agreement for the commercial manufacture and supply of naproxcinod active pharmaceutical ingredient (API) with Archimica in March 2008. NicOx recently announced the results of the second pivotal phase 3 study for naproxcinod in patients with osteoarthritis of the knee (the 302 study, see NicOx press release of September 15th, 2008). This study met all three of its co-primary efficacy endpoints and supported naproxcinod's non-detrimental effect on blood pressure.

Staffan Stromberg, Vice President of Technical Development and Operations at NicOx, said: "We are very happy to have concluded this agreement with Capsugel, which is recognized as the world leader in capsule manufacturing. We believe Capsugel's flexibility and production capacity is well adapted to NicOx' launch preparations for naproxcinod. This agreement is also the result of the excellent collaboration between the two companies, in which Capsugel's technology has been used in the production of naproxcinod clinical trial supplies."

Under the terms of this exclusive agreement, Capsugel will be responsible for the formulation and encapsulation of naproxcinod API, using its patented LEMS(TM) technology (Liquid Encapsul
'/>"/>

SOURCE NicOx
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. NicOx Announces Departure of Damian Marron for CEO Position
2. NicOx Signs Agreement for the Commercial Manufacture of Naproxcinod Drug Substance
3. NicOx Initiates Two Large ABPM Studies for Naproxcinod in Hypertensive Patients with Osteoarthritis
4. NicOx to Present at Financial Conferences in New York on November 27, 28 and 29
5. NicOx Opens U.S. Headquarters in New Jersey
6. Martek Signs Multi-Year Sole-Source Supply Agreement With Hero
7. Assay Designs(TM), Inc. and the Spinal Muscular Atrophy Foundation Announce Collaboration To Accelerate the Discovery of New Therapeutics for Spinal Muscular Atrophy (SMA)
8. Sigma-Aldrich Signs Exclusive Agreement With IsoSciences, LLC, to Distribute Isotopically Labeled Bioactive Compounds
9. BioNeutral Signs Agreement With a Non-profit for Long-Term Removal of Formaldehyde to Save 10,000 Mobile Homes in Louisiana
10. Carna Biosciences Signs Reagent Supply Agreement with Caliper Life Sciences
11. Lumidigm Signs Strategic Agreement with Methode Electronics : Automotive Supplier Invests in Biometric Component Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... , May 23, 2013 PuraMed ... developer, and marketer of over-the-counter (OTC) medicinal and ... research opinion on the company based on low ... , Non-Prescription, All Natural Product to Treat ... Product Outperforms #1 Prescription Competitor , Currently ...
(Date:5/23/2013)... (PRWEB) May 23, 2013 PI’s ... wide and provide 15 mm travel range with ... The small dimensions make these new positioners the ... spaces. A vacuum rated version is also available. ... specifications and datasheets can be found at: , ...
(Date:5/23/2013)... 23, 2013 Virobay, Inc. today announced that ... reached an important milestone, as Virobay has now initiated ... selective cathepsin S inhibitor.   The first ... placebo-controlled study designed to evaluate the safety, tolerability, pharmacokinetics ... adults. "The initiation of this Phase 1 ...
(Date:5/23/2013)... Z Trim Holdings, Inc. (OTC Markets: ZTHO), ... of industries, announced that Chef Erin Ryan ... year,s National Restaurant Association ("NRA") NRA Show, which was ... Research Chefs Association.  Chef Ryan spoke on the subject ... and the Ugly," joining four other prestigious panelists including: ...
Breaking Biology Technology:PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756 2PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756 3Precision Positioning System Uses Miniaturezed Piezo Linear Motor: LPS-24 Linear Stage by PI 2Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 2Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 3Z Trim's Chef Erin Ryan sits on Expert Panel at NRA Show 2Z Trim's Chef Erin Ryan sits on Expert Panel at NRA Show 3
... Fla., July 2 Bioheart, Inc. (Nasdaq:,BHRT) a ... of,autologous (patient-derived) cell therapies and devices for the ... it has been added to the,Russell Microcap Index ... of U.S. and global equity indexes on June ...
... Pharma, a leading provider of,knowledge management solutions to ... that the Aureus Pharma 2008 User Symposium will,be ... This symposium follows last year,s highly successful ... pharmaceutical and biotech customers,from both Europe and North ...
... 2 Research conducted at The,Walter and ... to a,major licensing agreement signed between Australian ... Merck,Serono., Under the Development and Licensing ... treatments for multiple sclerosis (MS) and other ...
Cached Biology Technology:Bioheart, Inc., Added to Russell Microcap Index 2Aureus Pharma Announces Date of 2008 Annual User Symposium 2MS Drug Development Agreement Based on WEHI's Medicinal Chemistry 2
(Date:5/23/2013)... fastest growing open-access publishers, announces the launch of ... Biotechnology . , A broad scope journal ... Biotechnology will provide a single open-access platform ... to be disseminated and discussed. , ... an open-science and interactive web platform for the ...
(Date:5/23/2013)... an age when microbial pathogens are growing increasingly resistant ... a team of Wisconsin scientists has synthesized a potent ... that cause staph infections. , Writing online in the ... group led by University of Wisconsin-Madison chemistry Professor Helen ... sensing" behavior of Staphylococcus aureus , a bacterium ...
(Date:5/22/2013)... Lung Screening Trial (NLST) investigators also conclude that ... with low-dose computed tomography (LDCT) versus chest X-ray ... paper is achievable at experienced screening centers in ... information to share with their patients about the ... following today,s publication in the New England ...
Breaking Biology News(10 mins):Frontiers launches new open-access journal in Bioengineering and Biotechnology 2University of Wisconsin chemists find new compounds to curb staph infection 2NLST: CT detects twice as many lung cancers as X-ray at initial screening exam 2NLST: CT detects twice as many lung cancers as X-ray at initial screening exam 3
... DC Could some women who naturally produce excess ... developing breast cancer? Results of a new animal study ... Georgetown Lombardi Comprehensive Cancer Center, a part of Georgetown ... August 15 Cancer Research, the investigators say ...
... North American Societies provides a comprehensive and in-depth documentation ... adapting to the varied ecosystems of North America during ... of recurrent themes and questions that have shaped debates ... impact on their local environments throughout the Holocene. ...
... (Vancouver August 11, 2011) Pregnant women taking prenatal ... new Vancouver-based study led by the Child & Family Research ... Canadian Journal of Public Health . The study ... reported taking supplements containing vitamin D, many were vitamin D ...
Cached Biology News:Higher estrogen production in the breast could confer greater cancer risk than thought 2Higher estrogen production in the breast could confer greater cancer risk than thought 3Pregnant women in Vancouver may not be getting enough vitamin D 2
... Blocker Arrays can be used to ... various proteins and sera that are commonly ... The array contains spots for 21 different ... Determination of antibody crossreactivity and species specificity, ...
High-throughput DNA preparation and end sequencing of BAC libraries. 3730xl DNA sequencers. LIMS tracking utilizing Geospiza's Finch system. Full-length BAC sequencing also available. Our expertise h...
... offers a full length insert sequencing service ... cosmids and fosmids. Agencourt utilizes unique ... libraries. There are several features that ... data with rapid turnaround including our patented ...
... maintenance, calibration, and validation (MCV) ... plate used for hands-free startup, ... using the Bio-Plex suspension array ... for use with Bio-Plex Manager ...
Biology Products: